Aachen, Germany (ots) - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in ...
STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi - European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA ...
Europäischer Rechnungshof - European Court of Auditors
Aachen, Germany & Toronto, Canada (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to ...
Suresnes, France (ots/PRNewswire) - - Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. - Growth over the financial year was driven by increased sales in oncology, particularly in the United States. - Several partnership agreements in oncology and neurology strengthen the Group's R&D portfolio in rare diseases. - Achieving 2025 ...
Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion - Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marketed by STADA - ...
STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...
Asklepios Kliniken GmbH & Co. KGaA
Wiesbaden, Germany (ots) - - Dr. Carl June and Dr. Michel Sadelain honored for groundbreaking CAR-T cell research in cancer therapy - One of the world’s most highly endowed medical prizes, with €1 million in prize money, awarded for the first time - Titia große Broermann: “With the Broermann Medical Innovation Award, we want to make outstanding medical ...
Europäischer Rechnungshof - European Court of Auditors
Europäischer Rechnungshof - European Court of Auditors
Europäischer Rechnungshof - European Court of Auditors
Europäischer Rechnungshof - European Court of Auditors
Kutsu tiedotustilaisuuteen 27. lokakuuta 2025 Paransivatko koronapandemiasta toipumiseen osoitetut miljardit EU:n liiketoimintaympäristöä? - Tiedotustilaisuus verkossa maanantaina 27. lokakuuta klo 10 00 Keski-Euroopan aikaa ...
Europäischer Rechnungshof - European Court of Auditors
Pressinbjudan till den 27 oktober 2025 Har alla miljarder som gått till återhämtningen efter covid förbättrat EU:s företagsklimat? - Presskonferens online måndagen den 27 oktober kl. 10.00 CET. - Offentliggörande samma ...
Zurich (ots) - Vaccentis, a Zurich based biotech company specializing in the development of therapeutic protein-based tumor vaccines, has signed a letter of intent with TrueMed, a leading commercialization partner. Accelerating cancer vaccine against renal cell carcinoma The aim of this letter of intent is to ...
Europäischer Rechnungshof - European Court of Auditors
Europäischer Rechnungshof - European Court of Auditors
Kan EU bota bristen på kritiska läkemedel? - Presskonferens online onsdagen den 17 september kl. 10.00 CEST. - Offentliggörande samma dag kl. 17.00 CEST. Europeiska revisionsrätten inbjuder härmed till en presskonferens online inför offentliggörandet av en särskild rapport om EU:s åtgärder för att säkerställa ...
Europäischer Rechnungshof - European Court of Auditors
Μπορεί η ΕΕ να θεραπεύσει τις ελλείψεις σε φάρμακα κρίσιμης σημασίας; - Διαδικτυακή ενημέρωση Τύπου: Τετάρτη 17 Σεπτεμβρίου, ...
Europäischer Rechnungshof - European Court of Auditors
Voiko EU löytää parannuskeinon lääkepulaan? - Tiedotustilaisuus verkossa keskiviikkona 17. syyskuuta klo 10.00 Keski-Euroopan kesäaikaa - Kertomus julkaistaan samana päivänä klo 17.00 Keski-Euroopan kesäaikaa Euroopan tilintarkastustuomioistuin kutsuu teidät ...
Suresnes, France (ots/PRNewswire) - - Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company - KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA - Acquisition ...
Technische Universität München
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Hollow microparticles for cargo molecules Slime as a material for multifunctional spheres - Hollow microspheres for molecular cargoes combine multiple functions - They adhere effectively to soft tissue and cartilage - Potential future applications in osteoarthritis or for oral ulcers Researchers at the Technical University of Munich (TUM) have developed hollow microspheres made ...
Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
Technische Universität München
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE A new biotech hub for Munich Where science powers start-ups: Launching BioLabs|TUM • TUM Venture Labs cooperate with BioLabs and Lilly • 1,800 square meters of coworking lab space • Aiming at accelerating therapy development BioLabs, TUM Venture Labs, and Eli Lilly and Company (Lilly) today launched BioLabs|TUM, a new biotechnology innovation hub in central Munich. The initiative aims to empower early-stage biotech start-ups ...
